<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:hpo ids='HP_0001649'>Tachycardia</z:hpo> and tachyarrhythmias are associated with increased morbidity and mortality in adult patients in the ICU </plain></SENT>
<SENT sid="1" pm="."><plain>This study examines the effects of nebulized <z:chebi fb="1" ids="35523">bronchodilator</z:chebi> therapy (<z:chebi fb="0" ids="2549">albuterol</z:chebi> and <z:chebi fb="0" ids="5956">ipratropium</z:chebi>) on heart rate and <z:hpo ids='HP_0011675'>arrhythmias</z:hpo> in this population and tests the proposition that <z:chebi fb="0" ids="8746">levalbuterol</z:chebi> is safer than <z:chebi fb="0" ids="2549">albuterol</z:chebi> in that regard </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: The design was a randomized, single-blind, crossover, prospective study in 70 critically ill adult patients treated with nebulized <z:chebi fb="1" ids="35523">bronchodilators</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>Patients were randomized to nebulized <z:chebi fb="0" ids="2549">albuterol</z:chebi> alternating with <z:chebi fb="0" ids="8746">levalbuterol</z:chebi> every 4 to 6 h </plain></SENT>
<SENT sid="4" pm="."><plain>Group A received <z:chebi fb="0" ids="2549">albuterol</z:chebi> 2.5 mg alternating with <z:chebi fb="0" ids="8746">levalbuterol</z:chebi> 0.63 mg </plain></SENT>
<SENT sid="5" pm="."><plain>Group B received <z:chebi fb="0" ids="2549">albuterol</z:chebi> 2.5 mg alternating with <z:chebi fb="0" ids="8746">levalbuterol</z:chebi> 1.25 mg </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients received nebulized <z:chebi fb="0" ids="46659,5957">ipratropium bromide</z:chebi> with each treatment </plain></SENT>
<SENT sid="7" pm="."><plain>Heart rate was recorded before and after each treatment </plain></SENT>
<SENT sid="8" pm="."><plain>Cardiac rhythm was continuously monitored using electronic telemetry units </plain></SENT>
<SENT sid="9" pm="."><plain>RESULTS: In group A, mean ± SD change in heart rate after <z:chebi fb="0" ids="2549">albuterol</z:chebi> 2.5 mg (n = 303) was 0.89 ± 4.5 beats/min compared with 0.85 ± 5.3 beats/min after <z:chebi fb="0" ids="8746">levalbuterol</z:chebi> 0.63 mg (n = 301) (P = .89) </plain></SENT>
<SENT sid="10" pm="."><plain>In group B (n = 114), heart rate decreased 0.16 ± 5.1 beats/min after <z:chebi fb="0" ids="2549">albuterol</z:chebi> 2.5 mg compared with an increase of 1.4 ± 5.4 beats/min after <z:chebi fb="0" ids="8746">levalbuterol</z:chebi> 1.25 mg (n = 118) (P = .03) </plain></SENT>
<SENT sid="11" pm="."><plain>Five events of <z:hpo ids='HP_0011675'>arrhythmias</z:hpo> (0.6%) occurred during the course of 836 treatments </plain></SENT>
<SENT sid="12" pm="."><plain>Four consisted of occasional <z:hpo ids='HP_0006682'>premature ventricular contractions</z:hpo> </plain></SENT>
<SENT sid="13" pm="."><plain>Only one patient stopped treatment because of a 5-beat run of <z:hpo ids='HP_0004756'>ventricular tachycardia</z:hpo> (one in 70 patients [1.4%]) </plain></SENT>
<SENT sid="14" pm="."><plain>CONCLUSIONS: In <z:e sem="disease" ids="C0010340" disease_type="Disease or Syndrome" abbrv="">critically ill</z:e> adult patients, nebulized <z:chebi fb="0" ids="2549">albuterol</z:chebi> and <z:chebi fb="0" ids="5956">ipratropium</z:chebi> does not cause significant <z:hpo ids='HP_0001649'>tachycardia</z:hpo> or tachyarrhythmias </plain></SENT>
<SENT sid="15" pm="."><plain>Substitution of <z:chebi fb="0" ids="8746">levalbuterol</z:chebi> for <z:chebi fb="0" ids="2549">albuterol</z:chebi> to avoid <z:hpo ids='HP_0001649'>tachycardia</z:hpo> and tachyarrhythmias is unwarranted </plain></SENT>
<SENT sid="16" pm="."><plain>TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT01151579; URL: www.clinicaltrials.gov </plain></SENT>
</text></document>